晚期非小细胞肺癌的化放疗序贯治疗

目的探讨吉西他滨联合顺铂治疗晚期非小细胞肺癌3周方案并序贯化放疗的疗效和不良反应。方法经病理和细胞学证实的晚期非小细胞肺癌患者,既往未进行化疗和放疗,临床上有可测量病灶(根据WHO标准),美国东部肿瘤协作组(ECOG)评分为0～2分,肝、肾功能基本正常。均给予吉西他滨和顺铂的联合化疗并序贯化放疗方案治疗。按照WHO的标准评价疗效和不良反应,并随访生存期。结果共入组43例患者,其中39例可评价疗效:19例(48.72%)部分缓解、13例(33.33%)病情稳定和7例(17.95%)疾病进展。生存期为3.7～21.4个月,中位生存期为10.1个月。主要的不良反应为血液毒性,表现为白细胞、中性粒细胞、血小板和血红蛋白下降;其次为消化道症状。结论吉西他滨联合顺铂治疗晚期非小细胞肺癌3周方案并序贯化放疗是晚期非小细胞肺癌的标准一线化疗方案之一,患者可较好耐受。

Sequential chemo-radiation therapy for advanced non-small-cell lung cancer

Objective To explore the curative effect and adverse reaction of gemcitabine combined with cisplatin 3-week regimen combined with sequential chemo-radiation therapy for patients with advanced non-small-cell lung cancer (NSCLC). Methods The patients with advanced NSCLC verified by pathology and cytology between January 2000 and October 2005 were chosen, who didn't undertake chemotherapy and radiotherapy in the past. They were found to have clinically measurable focus (based on WHO standard), ECOG score ranged from 0 to 2,liver and kidney's function were basically normal. They were all given gemcitabine combined with cisplatin 3-week regimen combined with sequential chemo-radiation therapy. Curative effect and adverse reaction were evaluated by WHO standard. Their survival time was followed up. Results Forty three cases were elected into the study group of those, curative effect in 39 cases could be evaluated. Nineteen of 39 cases were PR (48.72% ),13 cases were SD (33.33%) and 7 cases were PD (17.95%). Neutral survival time was 10.1 months, ranging from 3.7 to 21.4 months. The main adverse reaction was hematologic toxicity. The manifestation were WBC, neutrophile granulocyte, blood platelet and hemoglobin all decreased, then was digestive canal symptom. Conclusion It is an effective and well-tolerated treatment protocol gemcitabine combined with cisplatin 3-week regimen combined with sequential chemo-radiation therapy for patients with advanced NSCLC.